Divozilimab

Phase 3Monoclonal antibody

BBiocad

Divozilimab is one of 124 small molecule programs targeting Systemic Lupus Erythematosus. It is currently in Phase 3.

Indications

Total Trials

Active Trials

123

Competitors

Pipeline

Status by Indication[3][1]

Indication

Systemic Lupus ErythematosusActive, not recruiting

Neuromyelitis OpticaActive, not recruiting

Multiple SclerosisActive, not recruiting

Systemic SclerodermaActive, not recruiting

Systemic Lupus ErythematosusPhase 1

Active, not recruiting

Neuromyelitis OpticaPhase 3

Active, not recruiting

Multiple SclerosisPhase 3

Active, not recruiting

Systemic SclerodermaPhase 3

Active, not recruiting

Competition

Competitive Landscape

560 competitors in Multiple Sclerosis

#DrugCompanyPhaseTrials

Divozilimab

BBiocad

Phase 3

1 2

Betaseron

Bayer

Preclinical

16 3

Avonex

EMD Serono

Preclinical

22 4

Zinbryta

Roche

Preclinical

2 5

Myfortic

Novartis

Preclinical

—6

Circadin

NNeurim Pharmaceuticals Ltd.

Preclinical

3 7

Lunesta

Akero Therapeutics

Preclinical

1 8

Proair HFA

GGlaxo Dba Glaxosmithkline

Preclinical

1 9

Pletal

Otsuka

Preclinical

1 10

XEOMIN

MMerz Pharmaceuticals GmbH

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 3Active, not recruiting

Neuromyelitis Optica

NCT05730699

Q4 2026

Phase 1Recruiting

Systemic Lupus Erythematosus

NCT07136389

Q1 2027

Phase 3Active, not recruiting

Systemic Scleroderma

NCT05726630

Clinical

Trials by Indication[1]

Systemic Scleroderma1 trial

Clinical Study of Divozilimab in Patients With Systemic Scleroderma

Active, not recruiting·BBiocad·Phase 3·NCT05726630·152 enrolled

Neuromyelitis Optica1 trial

Efficacy and Safety of Divozilimab in Patients With Neuromyelitis Optica Spectrum Disorders (AQUARELLE)

Active, not recruiting·BBiocad·Phase 3·NCT05730699·105 enrolled

Multiple Sclerosis1 trial

An Extension Clinical Study of the Efficacy and Safety of BCD-132 in Patients With Multiple Sclerosis Who Previously Received Therapy in Clinical Studies of JSC BIOCAD

Completed·BBiocad·Phase 3·NCT06987851·44 enrolled

Systemic Lupus Erythematosus1 trial

Safety, Pharmacokinetics, Immunogenicity BCD-256-1 and Divozilimab in Subjects With Systemic Lupus Erythematosus

Recruiting·BBiocad·Phase 1·NCT07136389·135 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Divozilimab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Divozilimab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Divozilimab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Biocad company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 3[1]
Company: BBiocad

Divozilimab

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q4 2026

Q1 2027

Trials by Indication[1]

Systemic Scleroderma1 trial

Neuromyelitis Optica1 trial

Multiple Sclerosis1 trial

Systemic Lupus Erythematosus1 trial

References

Drug Info

Quick Facts

Related News